Within the GSE126044 immunotherapy cohort for NSCLC, we computed risk scores employing the identical formula and observed a marked distinction between individuals who responded to anti-PD-1 therapy and those who did not (Fig. 8A). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.